IGF1R and cancer: In contrast to the other investigated markers, the pooled prevalence of IGF1R was lower in grade III versus grade I cancers (41% versus 57%, p < 0.001; Additional file 25: Figure S4C), and was lower in T3 cancers compared to T1 cancers (39% versus 45%, p = 0.047; Additional file 26: Figure S4D).